Maze Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2026 Annual Meeting of Stockholders held by Maze Therapeutics, Inc. on June 8, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "MAZE".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
At the Annual Meeting, 44,660,029 shares were present virtually or by proxy, representing approximately 89.75% of outstanding shares entitled to vote, constituting a quorum. Stockholders voted on two proposals:
- Proposal 1: Election of Directors. Jason Coloma, Ph.D. and Neil Kumar, Ph.D. were elected as Class I directors to serve until the 2029 annual meeting.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Voting Data Table
| Nominee/Proposal | Votes For | Votes Withheld/Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Jason Coloma, Ph.D. | 35,792,536 | 5,926,467 | N/A | 2,941,026 |
| Neil Kumar, Ph.D. | 34,056,425 | 7,662,578 | N/A | 2,941,026 |
| Ratification of Auditors | 44,557,778 | 728 | 101,523 | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of newly elected directors Jason Coloma, Ph.D. and Neil Kumar, Ph.D. (serving until 2029).
- Confirm the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2026.
- Note the high attendance rate of 89.75% at the Annual Meeting.
- Review the definitive proxy statement filed on April 28, 2026, for detailed background on the proposals.